A Novel Liver-targeted Testosterone Therapy for Sarcopenia in Androgen Deprived Men With Prostate Cancer.

Handoo RheeAnojan NavaratnamIrina OleinikovaDeborah GilroyYolanda ScuderiPeter HeathcoteTuan V NguyenSimon WoodKen K Y Ho

Published in: Journal of the Endocrine Society (2021)

LTTT shows promise as a simple therapy for preventing sarcopenia and bone loss during ADT. LTTT may induce reversible PSA rise in some patients. Further studies are required to optimize LTTT dose in ADT. LTTT has potential application in other catabolic states in men and women.

Keyphrases

prostate cancer
bone loss
end stage renal disease
radical prostatectomy
newly diagnosed
ejection fraction
skeletal muscle
chronic kidney disease
peritoneal dialysis
cancer therapy
big data
drug delivery
risk assessment
patient reported outcomes
replacement therapy
patient reported